LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Optofluidic Device Quantifies CTCs in Blood

By LabMedica International staff writers
Posted on 25 Jul 2017
Image: The device employs two systems in miniature: a flow system and an optical system. The ratio of the two systems provides a quantitative indication about how the cancer is progressing (Photo courtesy of the Universitat Rovira i Virgili).
Image: The device employs two systems in miniature: a flow system and an optical system. The ratio of the two systems provides a quantitative indication about how the cancer is progressing (Photo courtesy of the Universitat Rovira i Virgili).
Researchers have developed a portable device that rapidly detects and counts circulating tumor cells (CTCs) in blood samples. It can help provide early diagnosis and help assess a patient’s level of health with convenient, inexpensive, effective testing for monitoring patients with cancer.

These patients need to be constantly monitored during treatment to assess disease progression, particularly if their cancer has metastasized. Monitoring is currently done using imaging techniques and biopsies, which are invasive and not always possible. In contrast, the new device is highly sensitive and requires no surgery or treatment involving radiation, thus improving patient quality of life.

The device was developed by a team of researchers and clinicians led by Universitat Rovira i Virgili (Tarragona, Catalonia, Spain) professors Francesc Díaz, Ramon Álvarez Puebla, and Jaume Masons and by HM Torrelodones University Hospital’s Dr. Eduardo García–Rico. It counts the number of tumor cells in a blood sample in real time, and has been successfully tested on patients in various stages of breast cancer. It can be adapted for use to determine the presence of other tumors by analyzing for different antibodies in the blood sample.

The patented device has been licensed for commercialization to Medcom Science, a company engaged in research and development of technologies for diagnosing and treating cancer.

The study, by Pedrol E et al, was published June 16, 2017, in the journal Scientific Reports.

Related Links:
Universitat Rovira i Virgili

Gold Member
Collection and Transport System
PurSafe Plus®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
6 Part Hematology Analyzer with RET + IPF
Mispa HX 88
Sample Transportation System
Tempus1800 Necto

Channels

Hematology

view channel
Image: Research has linked platelet aggregation in midlife blood samples to early brain markers of Alzheimer’s (Photo courtesy of Shutterstock)

Platelet Activity Blood Test in Middle Age Could Identify Early Alzheimer’s Risk

Early detection of Alzheimer’s disease remains one of the biggest unmet needs in neurology, particularly because the biological changes underlying the disorder begin decades before memory symptoms appear.... Read more
GLOBE SCIENTIFIC, LLC